Bioscience


Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date

September 1st, 2022 - Ryan Allway

San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to its special meeting to be held online on September 30, 2022.   Stockholders as […]

Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion

June 30th, 2022 - Ryan Allway

Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies   San Diego, California–(Newsfile Corp. – June 30, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory […]

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

June 27th, 2022 - Ryan Allway

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th   SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, […]

Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer

March 28th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to […]

Skye Bioscience Announces $7.0 Million Registered Direct Offering

September 27th, 2021 - Ryan Allway

SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced that it has entered into securities purchase agreements with several institutional investors, for the purchase and sale […]

Big Pharma Dives Into CBD: Who Could Be Next?

February 22nd, 2021 - Robin Lefferts

As many of you know, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) agreed in early February to acquire GW Pharmaceuticals plc (NASDAQ: GWPH) for a total price tag, including cash and shares, of $7.2 billion. GW Pharma is a pioneer in cannabinoid-based medicine, and its cannabidiol (CBD) formulation Epidiolex® is notably the first plant-derived cannabinoid medicine ever […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Pure Extracts Unveils Plans for Functional Mushrooms

November 30th, 2020 - Ryan Allway

  There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health. At the […]

Science-driven Brand Delivers 5 Perfected Cannabis Highs

April 6th, 2020 - Robin Lefferts

What happens when the investment environment surrounding cannabis companies evaporates amid concerns about overvaluations and lack of returns? And then, a worldwide pandemic reverses years of economic growth almost overnight, plunging economies into near-instant depression? One thing that happens is some quality companies become distressed, offering investors the opportunity to purchase a stake at a […]

Coping With Stress During the COVID-19 Outbreak with CBD & Adaptogens

April 2nd, 2020 - Ryan Allway

The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other side-effects. It’s important for everyone to take inventory of their health and […]

Israel Begins Cannabis Exports to Meet Unmet Medical Needs

March 30th, 2020 - Ryan Allway

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s […]

Canadian Cannabis Success Being Replayed in Israel Right Now, Featuring an Exclusive Isracann Biosciences CEO Video Interview Part #1

December 18th, 2019 - Ryan Allway

After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now President and CEO of Isracann Biosciences (CSE: IPOT) (OTCPK: ISCNF), Israel’s first pure-play cannabis company to […]

What if Employers had a Convenient Way to Test for Cannabis Use?

October 11th, 2019 - Robin Lefferts

  With cannabis legalization sweeping across North America after decades of prohibition, there are some natural concerns surrounding the introduction of the drug to the legal marketplace. In the area of safety, most of the questions have surrounded the issue of impaired driving. One topic that hasn’t gotten a lot of press is that of […]

Europe: The Cannabis Industry’s Next Emerging Market

September 19th, 2019 - Ryan Allway

The global cannabis industry is projected to reach $66.3 billion by 2025, according to Grand View Research, representing a 23.9 percent compound annual growth rate. While North America has become a market leader, European markets are quickly catching up with their own liberalized laws. The market for health and wellness products, such as cannabidiol (CBD) […]

More Companies Lining Up to Get Their Hands on Lexaria’s DehydraTECH™ Platform

August 15th, 2019 - Ash Stringer

When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology that enhances qualities and uptake of all sorts […]

The Yield Growth Corp.: Headed by a Team of Powerful Women Leaders

August 9th, 2019 - Joy Crosby

  As an emerging and relatively new line of business, cannabis has already proven itself to be a powerhouse of a market. The global cannabis industry’s revenue ballooned to US $12.2 billion in 2018, with predictions that it will reach $16.9 billion in 2019, according to BDS Analytics. The burgeoning industry is setting trends in […]

XPhyto Therapeutics Ready to Be Cannabis’ Newest Public Entity

August 2nd, 2019 - Ryan Allway

Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission, XPhyto is ready to go public on the CSE under the ticker “XPHY”. The company will […]

First, Last and Always: Cannabis Innovation Never Ends in Israel

July 25th, 2019 - Ash Stringer

When the word “cannabis” is heard, “Israel” probably isn’t one of the first things that jumps to mind. But, for investors it should be. For that matter, so should EuroMed Therapeutics, an upstart heading toward the public domain. Here’s why. Top Notch R&D, Perfect Weather and Locale  First, simply consider the overall startup picture and […]

Synthetic Cannabinoids: The New Age of Medical Marijuana

July 22nd, 2019 - Ryan Allway

Believe it or not, the world’s first blockbuster drug is still one of the most commonly used today. Acetylsalicylic acid, better known as Aspirin®, is a synthetic derivative of the natural substance salicylic acid, an extract from the bark of the white willow tree. Any company would like to invent a drug that enjoys 100+ […]

RYAH Medtech announces CE Mark for its RYAH vaporizer to establish critical plant-based dose measuring and data analytics in the European market

June 24th, 2019 - Ryan Allway

NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) — RYAH Medtech Inc. (“RYAH” or the “Company”), announced today that it has received a CE Mark for its dose measuring and data aggregator vaporizer. The certification is a critical part of RYAH’s expansion strategy in the European region for the RYAH dose-measuring plant-based vaporizer, RYAH proprietary dry […]

A Top Selling Product and a CEO Buying Shares Sets This Cannabis Company Apart

June 19th, 2019 - Ash Stringer

Cannabis in Canada has a long and storied history, going back to 1923 when the plant was added to the Confidential Restricted List as a prohibited drug. Fast-forward to 2001 and regulators loosened laws to allow medical use to treat certain conditions under the MMPR (Marijuana for Medical Purposes Regulations). Then, in October 2017, history […]

Betting Big on the New Age of Synthetic Cannabinoids

June 18th, 2019 - Ash Stringer

In the U.S. and globally, there is an explosion in demand for cannabinoids, naturally occurring components of the cannabis plant, for medical research purposes.  The overarching problem, however, is that the natural extraction technologies that dominate the field today are chock full of issues, including high costs and potential for contamination.  While the bias still […]

FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division

June 4th, 2019 - Ryan Allway

The cannabis industry is quickly maturing from home grows and bongs to industrial-scale cultivation and innovative new product formats. At the core of this transformation, science is helping transform medical cannabis into cutting-edge pharmaceuticals and recreational cannabis into compelling alternatives to tobacco and alcohol. Companies that recognize the role of science are best positioned to […]

Pascal Biosciences Announces Formation of Clinical Advisory Board

May 8th, 2019 - Ryan Allway

Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical […]

Why Branding Matters in the Cannabis Industry

April 16th, 2019 - Ryan Allway

The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a blistering 34.6 percent compound annual growth rate. While the industry is known for strain names, like OG Kush and Girl Scout Cookies, there aren’t established marquee brands like those found in tobacco or pharmaceutical industries—which has […]

Harvest One Ensures Cannabis Supply with Greenbelt Acquisition

April 9th, 2019 - Ryan Allway

Vertical integration has become kind of a buzzword in the cannabis industry over the last few years. Many companies claim it as a goal, with the intent of controlling the whole supply chain for their products from seed-to-sale. Getting to that level of control can prove difficult, however, as the resources, equipment, and expertise required […]

International Cannabis Exploring Listing on Major International Exchange

April 4th, 2019 - Ryan Allway

VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) — ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (“ICC” or “International Cannabis” or the “Company”) is pleased to announce its intentions to pursue a public listing on a major international stock exchange. ICC is currently evaluating the strategic advantages derived from a potential listing on the NASDAQ, the New York […]

Harvest One Executing on Brands and Distribution Strategy

March 27th, 2019 - Ryan Allway

The nature of the compelling stories in the cannabis industry has changed over the last few years. Remember when a late-stage ACMPR applicant was all the rage? Then it was production expansion and funded capacity. Now, all of that potential is turning to the reality of any market – who can sell product and generate […]

Halo Labs Announces Repricing of Convertible Debenture Units and An Increase in The Expected Size of The Offering

March 15th, 2019 - Ryan Allway

TORONTO Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTC: AGEEF, Germany: A9KN) announces that it has agreed to amend the terms of its previously announced “best efforts” offering (the “Offering”) of convertible debenture units (the “Convertible Debenture Units”) to lower the conversion price at which the convertible debentures are convertible into common shares of […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading